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Massimo D’Armiento, MD
Dario Giugliano, MD, PhD
ERECTILE DYSFUNCTION IS AN IM-portant cause of decreased qual-ity of life in men,1-3 and mayaffect an estimated 30 million
men in the United States.3 In the Health
Professionals Follow-up Study, mod-
erate to severe erectile dysfunction was
reported by 12% of men younger than
59 years; 22% of men aged 60 to 69
years; and 30% of men older than
69 years.4
Moreover, several modifiable life-
style factors, including physical activ-
ity and leanness, were associated with
maintenance of erectile function. For
instance, men with a body mass index
(BMI, calculated as weight in kilo-
grams divided by the square of height
in meters) higher than 28.7 have a 30%
higher risk for erectile dysfunction than
those with a normal BMI (25).4 The
prevalence of overweight or obesity in
men reporting symptoms of erectile
dysfunction may be as high as 79%,5 al-
though vascular risk factors com-
monly associated with obesity also may
play an important role.6
Obesity is an independent risk fac-
tor for cardiovascular disease,7 and is
associated with elevated levels of sev-
eral proinflammatory cytokines, such
as interleukin 6 (IL-6), interleukin 8
(IL-8), and C-reactive protein (CRP),
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Context Healthy lifestyle factors are associated with maintenance of erectile func-
tion in men.
Objective To determine the effect of weight loss and increased physical activity on
erectile and endothelial functions in obese men.
Design, Setting, and Patients Randomized, single-blind trial of 110 obese men
(body mass index 30) aged 35 to 55 years, without diabetes, hypertension, or hy-
perlipidemia, who had erectile dysfunction that was determined by having a score of
21 or less on the International Index of Erectile Function (IIEF). The study was con-
ducted from October 2000 to October 2003 at a university hospital in Italy.
Interventions The 55 men randomly assigned to the intervention group received de-
tailed advice about how to achieve a loss of 10% or more in their total body weight by
reducing caloric intake and increasing their level of physical activity. Men in the control
group (n=55) were given general information about healthy food choices and exercise.
MainOutcomesMeasures Erectile function score, levels of cholesterol and tryglyc-
erides, circulating levels of interleukin 6, interleukin 8, and C-reactive protein, and en-
dothelial function as assessed by vascular responses to L-arginine.
Results After 2 years, bodymass index decreasedmore in the intervention group (from
a mean [SD] of 36.9 [2.5] to 31.2 [2.1]) than in the control group (from 36.4 [2.3] to
35.7 [2.5]) (P.001), as did serum concentrations of interleukin 6 (P=.03), and C-
reactive protein (P=.02). The mean (SD) level of physical activity increased more in the
intervention group (from 48 [10] to 195 [36]min/wk; P.001) than in the control group
(from 51 [9] to 84 [28] min/wk; P.001). The mean (SD) IIEF score improved in the
intervention group (from 13.9 [4.0] to 17 [5]; P.001), but remained stable in the con-
trol group (from 13.5 [4.0] to 13.6 [4.1]; P=.89). Seventeen men in the intervention
group and 3 in the control group (P=.001) reported an IIEF score of 22 or higher. In
multivariate analyses, changes in body mass index (P=.02), physical activity (P=.02),
andC-reactive protein (P=.03)were independently associatedwith changes in IIEF score.
Conclusion Lifestyle changes are associated with improvement in sexual function
in about one third of obese men with erectile dysfunction at baseline.
JAMA. 2004;291:2978-2984 www.jama.com
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a marker of inflammation.8-11 Markers
of low-grade inflammation are posi-
tively associated with endothelial dys-
function in human obesity.8,10 Erectile
and endothelial dysfunctions may have
some shared pathways12 through a de-
fect in nitric oxide activity, which may
be inhibited through age-, disease-, and
behavioral-related pathways. In theory,
intervention in modifiable health be-
haviors, especially reducing body
weight and increasing physical activ-
ity, may reduce the risk of both erec-
tile dysfunction and endothelial dys-
function in obese men, but this
hypothesis has not been tested.
The aim of this randomized con-
trolled trial of obese men with erectile
dysfunction was to determine if life-
style changes designed to obtain a sus-
tained and long-term reduction in body
weight (10% of initial weight main-
tained for 2 years) and an increase in
physical activity positively affect erec-
tile and endothelial functions.
METHODS
Obese men with erectile dysfunction,
aged 35 to 55 years, were recruited from
the outpatient department for weight
loss at the Second University of Naples,
Naples, Italy, in October 2000. The trial
ended in October 2003. Erectile func-
tion was assessed by completing ques-
tions 1 to 5 on the International Index
of Erectile Function (IIEF), which is a
multidimensional questionnaire.13 The
5 questions asked were (1) How often
were you able to get an erection during
sexual activity?; (2) When you had erec-
tions with sexual stimulation, how of-
ten were your erections hard enough for
penetration?; (3) When you attempted
sexual intercourse, how often were you
able to penetrate (enter) your partner?;
(4) During sexual intercourse, how of-
ten were you able to maintain your erec-
tion after you had penetrated (entered)
your partner?; and (5) During sexual in-
tercourse, how difficult was it to main-
tain your erection to completion of in-
tercourse? The IIEF score represents the
sum of questions 1 to 5, with a maxi-
mum score of 25; a score of 21 or less
indicates erectile dysfunction.
We assessed 140 men with IIEF scores
lower than 22 to determine eligibility.
These men had no evidence of partici-
pation in diet reduction programs within
the last 6 months and had completed a
health and medical history question-
naire, which served as a screening tool.
Exclusion criteria were diabetes melli-
tusor impairedglucose tolerance(plasma
glucose levels of 140-200 mg/dL [7.8-
11.1 mmol/L] 2 hours after a 75-g oral
glucose load), impaired renal function,
including macroalbuminuria, pelvic
trauma, prostatic disease, peripheral or
autonomic neuropathy, hypertension
(blood pressure140/90 mm Hg), car-
diovascular disease, psychiatric prob-
lems, use of drugs or alcohol abuse
(500 g of alcohol per week in the last
year). After the exclusion of 30 ineli-
gible men, 110 obese, sedentary (1
hour per week of physical activity) men
were enrolled in the trial. The study was
approved by the institutional commit-
tee of ethical practice at the Second Uni-
versity of Naples. Participants provided
informed written consent for volun-
tary, unpaid participation.
Men were randomly assigned to
either the intervention or control group
using a computer-generated random
number sequence (FIGURE 1). Alloca-
tion was concealed in sealed study fold-
ers that were maintained at a central,
secure location until after informed con-
sent was obtained. The nurses who
scheduled the study visits did not have
access to the randomization list. How-
ever, the staff members involved in the
intervention had to be aware of the
group assignment; thus, the study was
only partially blinded. Laboratory staff
did not know the participants’ group
assignments.
Men in the intervention group were
given detailed advice about how to
achieve a reduction in total body weight
of 10% or more. The program con-
sisted of instruction regarding reduc-
ing caloric intake, setting goals, and self-
monitoring (food diaries) through a
series of monthly small group ses-
sions. Behavioral and psychological
counseling was also offered. The mean
daily caloric intake was 1700 kcal for
the first year and 1900 kcal for the sec-
ond year. The recommended compo-
sition of the dietary regimen per 1000
kcal was carbohydrates, 50% to 60%;
proteins, 15% to 20%; total fat, less than
30%; saturated fat, less than 10%; mono-
unsaturated fat, 10% to 15%; polyun-
saturated fat, 5% to 8%; and fiber, 18
g. Dietary advice was tailored to each
man on the basis of food records col-
lected on 3 nonconsecutive days and
completed the week before the meet-
ing with the nutritionist. These men also
received individual guidanceon increas-
ing their level of physical activity,
mainly walking, but also swimming or
aerobic games (ie, football, baseball,
soccer). Men were in the program for
2 years. They had monthly sessions with
the nutritionist and exercise trainer dur-
ing the first year and bimonthly ses-
sions during the second year. Compli-
ance with the program was assessed by
attendance at the meetings and comple-
tion of the food diaries.
Men in the control group were given
general oral and written information
about healthy food choices and exer-
cise at baseline and at subsequent bi-
monthly visits, but no specific indi-
vidualized program was provided.
Height and weight were recorded
with participants wearing lightweight
clothing and no shoes using a Seca 200
Figure 1. Flow of Patients Through the Trial
30 Ineligible
20 Did Not Meet
Protocol
Eligibility Criteria
10 Unwilling to
Participate
140 Men Assessed for Eligibility
3 Withdrew
and Declined
Follow-up
3 Withdrew
and Declined
Follow-up
55 Assigned
to Control
Group
55 Assigned to
Intervention
Group
55 Included in
Analysis
55 Included in
Analysis
110 Randomized
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scale (Seca, Hamburg, Germany) with
attached stadiometer. Waist-to-hip ra-
tio (WHR) was calculated as waist cir-
cumference in centimeters divided by
hip circumference in centimeters.
Twenty-four hour nutrient intakes were
calculated with food-composition tables
and patients’ weekly food diaries. All
men were asked to complete a record
of food intake for 3 days to assess di-
etary adherence and to record occupa-
tional, household, and leisure-time
physical activity to assess exercise ac-
tivity. Foods were measured using stan-
dard measuring cups and spoons and
weight-approximation diagrams. No
participants in either group took any
drug specific for erectile dysfunction at
baseline (exclusion criterion); how-
ever, if during the course of the study
there was a need for such use, this was
discussed and recorded.
Endothelial function was assessed
with the L-arginine test, as previously
described.14 Briefly, an intravenous bo-
lus of 3 g of L-arginine (10 mL of a 30%
solution of L-arginine monochloride),
the natural precursor of nitric oxide,
was injected intravenously within 60
seconds. Blood pressure and platelet ag-
gregation response to 1.25 µmol of
adenosine diphosphate were mea-
sured before L-arginine injection and af-
ter 10 minutes. L-arginine mimics some
of the effects of nitric oxide, including
vasodilatation and antiplatelet activ-
ity; because the vascular effects of L-
arginine are thought to derive from
metabolic conversion to nitric oxide, the
L-arginine test has been used for evalu-
ating endothelial function.15 In our labo-
ratory, following the L-arginine bolus
(difference between basal and 10-
minute values) in a matched control
group of nonobese men (n=50), there
was a decrease in platelet aggregation
by 13% and a mean (SD) decrease in
blood pressure by 6.5 (1.5) mm Hg.4
Assays for serum levels of total and
high-density lipoprotein cholesterol, tri-
glycerides, and glucose were per-
formed in the hospital’s chemistry labo-
ratory. Plasma insulin levels were
assayed by radioimmunoassay (Ares, Se-
rono, Italy). Serum samples for cyto-
kine and CRP levels were stored at
−80°C prior to being assayed. Serum
concentrations of IL-6 and IL-8 were de-
termined in duplicate using a highly sen-
sitive, quantitative sandwich enzyme as-
say (Quantikine HS, R&D Systems,
Minneapolis, Minn). High-sensitivity
CRP was assayed by immunonephelom-
etry on Behring Nephelometer 2 (Dade
Behring, Deerfield, Ill). In our labora-
tory, the medians (interquartile ranges)
for these values were 2.1 pg/mL (0.3-
5.2 pg/mL) for IL-6; IL-8, 3.1 pg/mL
(0.8-6.2 pg/mL); and CRP, 0.7 mg/L
(0.2-3.2 mg/L). These values are based
on 50 healthy, nonobese men who were
matched to obese men for age and meta-
bolic characteristics.
Data are presented as mean (SD) un-
less otherwise indicated and were ana-
lyzed using the intention-to-treat prin-
ciple. We compared baseline data using
a t test for continuous variables and the
Wilcoxon test for IL-6, IL-8, and CRP.
We compared risk factors and nutrient
intake after 2 years using a t test based
on the values at the end of follow-up and
a t test based on differences from base-
line. Results of the analysis omitting pa-
tients lost during follow-up did not dif-
fer from that including the last available
records; data are therefore shown for the
analysis that includes all men as ran-
domized. Spearman rank correlation co-
efficients were used to quantify the re-
lationships between metabolic variables
and cytokine levels. The effects of in-
tervention on IIEF score, indices of en-
dothelial function, and cytokine levels
were tested by means of paired t tests and
a Wilcoxon matched test. The2 test was
used for comparing proportions of men
in the 2 groups that obtained erectile
function after treatment. Multivariate re-
gression analysis tested the indepen-
dent association and contribution of
changes in BMI, WHR, physical activ-
ity, indices of endothelial function, and
plasma cytokine concentrations with the
dependent variable (changes in IIEF
score), and also included baseline IIEF
score as a covariate. P.05 was consid-
Table 1. Characteristics of the Study Participants*
Characteristic
Intervention Group
(n = 55)
Control Group
(n = 55)
P
Value
Age, y 43.5 (4.8) 43 (5.1) .62
Weight, kg 103 (9.4) 101 (9.7) .55
Body mass index† 36.9 (2.5) 36.4 (2.3) .65
Waist-to-hip ratio 1.02 (0.09) 1.01 (0.09) .75
Erectile dysfunction score‡ 13.9 (4) 13.5 (4) .55
Blood pressure, mm Hg
Systolic 127 (7.5) 128 (7.7) .49
Diastolic 86 (3.7) 85 (4.1) .48
Cholesterol level, mg/dL
Total 213 (32) 210 (29) .45
High-density lipoprotein 39 (10) 40 (9) .76
Triglycerides, mg/dL 169 (56) 174 (51) .23
Glucose, mg/dL 103 (10) 104 (11) .77
Insulin, µU/mL 21 (8) 19 (7) .35
Interleukin, pg/mL§
6 4.5 (1.9-9) 4.4 (2-8.6) .39
8 5.3 (2.3-10) 5.0 (2.2-9.7) .45
C-reactive protein, mg/L§ 3.3 (1.2-8.1) 3.4 (1.2-8.3) .37
Response to L-arginine
Platelet aggregation, % −4 (2.2) −3.6 (2.1) .19
Mean blood pressure, mm Hg −2.5 (1.3) −2.4 (1.4) .27
SI conversion factors: To convert total cholesterol and high-density lipoprotein cholesterol from mg/dL to mmol/L, mul-
tiply by 0.0259; glucose from mg/dL to mmol/L, multiply by 0.0555; insulin from µU/mL to pmol/L, multiply by 7.175;
and triglycerides from mg/dL to mmol/L, multiply by 0.0113.
*Data are presented as mean (SD) unless otherwise indicated.
†Calculated as weight in kilograms divided by the square of height in meters.
‡Based on the International Index of Erectile Function (range, 1-25).
§Data are presented as median (interquartile range).
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ered statistically significant. All analy-
sis were conducted using SPSS statisti-
cal software (version 9.0, SPSS Inc,
Chicago, Ill).
RESULTS
One hundred ten men were randomly
assigned to the intervention (n=55) or
control group (n=55) (Figure 1). Both
groups were comparable and relatively
healthy (TABLE 1). The prevalence of
smokerswassimilar in the2groups:27%
in the intervention group and 31% in the
control group (P=.34). All men were
obese, with BMI values ranging from 30
to 49. The mean erectile function score
was also comparable between groups
with values ranging from 7 to 19 in the
intervention group and from 7 to 20 in
the control group. As expected for an
obesemalepopulation, serumIL-6, IL-8,
and CRP levels were higher than previ-
ously reported in nonobese men.8,11
Spearman rank correlation coefficients
between IIEF score and metabolic vari-
ables are shown in TABLE 2. Univariate
correlations are provided, but they were
scarcely affected by adjustment for age.
Erectile function score was positively
associated with mean blood pressure
responses to L-arginine and negatively
associated with BMI, WHR, and CRP.
After 2 years of follow-up, there were
3 dropouts in the intervention group
and 3 in the control group, all of which
occurred after 24 weeks of follow-up.
Dropouts from the intervention group
showed a decrease in body weight af-
ter 24 weeks of follow-up, suggesting
that they were adhering to the lifestyle
changes. Five men in the control group
and 4 in the intervention group used
pharmacological therapy for erectile
dysfunction (phosphodiesterase type 5
inhibitors) during the course of the
study; however, excluding these men
in the analysis did not affect the re-
sults, and therefore data are pooled for
all participants.
Baseline data showed no important
difference in nutrient intake between the
2 groups (TABLE 3). After 2 years, pa-
tients in the intervention group com-
pared with the control group con-
sumed a greater percentage of calories
from complex carbohydrates, protein,
and monounsaturated fat; had a greater
intake of fiber; had a lower ratio of
omega-6 to omega-3 fatty acids; and had
lower intakes of total calories, satu-
rated fat, and cholesterol (Table 3). The
level of physical activity increased more
in the intervention group (from 48 [10]
to 195 [36] min/wk) than in the con-
trol group (from 51 [9] to 84 [28] min/
wk; P.001).
After 2 years, men in the interven-
tion group had significant decreases in
body weight, BMI, WHR, blood pres-
sure, levels of glucose, insulin, total
cholesterol and triglycerides, but a sig-
nificant increase in high-density lipo-
protein cholesterol (TABLE 4). There
was no significant change in these pa-
rameters among men in the control
group (Table 4). Serum concentra-
tions of IL-6 and CRP were signifi-
cantly reduced in the intervention
group compared with the control group.
Erectile function score improved in the
intervention group, but remained stable
in the control group (FIGURE 2). Sev-
enteen men in the intervention group
and 3 in the control group (P=.001) re-
ported an IIEF score of 22 or higher.
Thus, 31% of men in the intervention
group regained sexual function.
In the intervention group, changes
in IIEF score were related to the reduc-
Table 2. Correlations With Erectile
Dysfunction Score in Obese Men (N = 110)
Characteristic
Correlation
Coefficient
P
Value
Weight −0.45 .01
Body mass index −0.37 .02
Waist-to-hip ratio −0.49 .007
Cholesterol level
Total −0.15 .06
High-density
lipoprotein
0.08 .09
Triglycerides −0.09 .12
Glucose −0.08 .15
Insulin −0.04 .24
Interleukin*
6 −0.10 .06
8 −0.17 .05
C-reactive protein* −0.25 .03
Response to L-arginine
Platelet aggregation 0.14 .06
Mean blood pressure 0.28 .03
*Log-transformed data.
Table 3. Nutrient Indices at Entry to Study and After 2 Years
Nutrient
Intervention Group (n = 55) Control Group (n = 55)
Corrected
Difference
in Mean Change
at 2 Years (95% CI)
P Value
at 2 Years
Mean (SD)
P
Value
Mean (SD)
P
ValueBaseline 2 Years Baseline 2 Years
Total energy, kcal/d 2340 (205) 1950 (168) .01 2390 (215) 2340 (174) .07 −340 (−520 to −160) .01
Carbohydrates, %
Regular 57 (2.5) 55 (2.9) .01 57 (2.1) 57 (2.9) .56 −2 (−3.4 to −0.6) .02
Complex 43 (3.7) 50 (2.5) .001 39 (2.4) 40 (2.2) .15 6 (2 to 4) .001
Fiber, g/d 15 (1.5) 25 (1.7) .01 15 (1.6) 16 (1.8) .10 9 (5 to 13) .009
Protein, % 13 (1.9) 16 (1.7) .02 13 (1.8) 14 (1.7) .08 2.0 (0.5 to 3.5) .04
Fat, % 30 (2.6) 29 (2.7) .06 30 (3.3) 29 (2.9) .59 0 (−1 to 1) .90
Saturated 14 (2.5) 9 (1.3) .01 14 (2.4) 14 (2.5) .90 −5 (−9 to −1) .001
Monounsaturated 9 (1.4) 14 (1.7) .01 10 (1.6) 10 (1.4) .95 5 (1.5 to 8.5) .01
Polyunsaturated 7 (1.2) 6 (0.9) .07 6 (1.1) 5 (0.8) .09 0 (−1.5 to 1.5) .88
Ratio of omega-6 to omega-3 fatty acid 12 (2.4) 6 (0.9) .001 13 (2.1) 12 (1.9) .08 −5 (−9 to −1) .001
Cholesterol, mg/d 360 (39) 276 (26) .01 356 (40) 327 (31) .05 −53 (−95 to −11) .02
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tions in BMI (r=−0.35; P=.02) and in-
creases in the level of physical activity
(r=0.40, P=.02). The relationship be-
tween BMI and IIEF score was continu-
ous in this population, with no evi-
dence of a threshold effect. These
associations remained statistically sig-
nificant after performing a multivari-
ate analysis in which IIEF score was the
dependent variable and BMI, WHR,
level of physical activity, indices of en-
dothelial function, baseline IIEF score,
and serum CRP concentrations were the
independent variables. Body mass in-
dex (25% of the variance; P= .02),
physical activity (26% of the variance;
P= .02), and CRP (18% of the vari-
ance; P=.03) were independent pre-
dictors of IIEF score and explained al-
most 68% of the variability in score
changes.
COMMENT
In this study, we tested the hypothesis
that lifestyle changes aimed at reduc-
ing body weight and increasing physi-
cal activity would induce ameliora-
tion of erectile and endothelial
functions in obese men. The physi-
ological rationales underlying this hy-
pothesis are that healthy lifestyle fac-
tors are associated with maintenance of
good erectile function in men4; obe-
sity has been positively associated with
endothelial dysfunction and increased
serum concentrations of vascular in-
flammatory markers9,10; and both en-
dothelial and erectile dysfunction may
share some common metabolic and vas-
cular pathways that may be influ-
enced by behavioral-related path-
ways.16,17
Obese men with erectile dysfunc-
tion had evidence of abnormal endo-
thelial function, which was indicated
by reduced blood pressure and
platelet aggregation responses to
L-arginine and elevated serum concen-
trations of markers of low-grade in-
flammation, such as IL-6, IL-8, and
CRP. In the baseline cross-sectional
analysis of all 110 obese men, we ob-
served significant associations be-
tween IEEF score and proxy indica-
tors of elevated body fat, the vascular
response to L-arginine, and circulat-
ing IL-8 and CRP levels. The associa-
tion we found between IEEF score and
indices of endothelial dysfunction sup-
ports the presence of common vascu-
Figure 2. Individual Changes in Erectile
Function Score of Obese Men
IIE
F 
S
co
re
24
16
20
12
8
4
Baseline
Intervention Group 
(n = 55)
Control Group
(n = 55)
2 Years Baseline 2 Years
IIEF indicates International Index of Erectile Func-
tion. Datamarkers with error bars indicate mean (SD).
Table 4. Clinical and Metabolic Characteristics of the Study Participants after 2 Years*
Characteristic
Intervention Group (n = 55) Control Group (n = 55) Corrected
Difference
in Mean Change
at 2 Years (95% CI)
P Value
at 2 Years2 Years
Mean
Change
P
Value 2 Years
Mean
Change
P
Value
Weight, kg 88 (8.5) −15 .001 99 (9.2) −2 .27 −13 (−18 to −11) .007
Body mass index† 31.2 (2.1) −5.7 .001 35.7 (2.5) −0.7 .19 −5 (−7.5 to −2.5) .001
Waist-to-hip ratio 0.93 (0.08) −0.09 .001 1.00 (0.09) −0.01 .56 −0.08 (−0.12 to −0.06) .01
Erectile dysfunction score‡ 17 (5) 3.01 .001 13.6 (4.1) 0.1 .89 3 (1.2 to 4.8) .008
Blood pressure, mm Hg
Systolic 124 (7.4) −3 .04 127 (7.8) −1 .50 −2 (−3 to −1) .01
Diastolic 82 (3.6) −4 .02 85 (4.5) 0 .98 −4 (−6.5 to −1.5) .009
Cholesterol level, mg/dL
Total 202 (24) −11 .04 212 (31) 2 .72 −13 (−23 to −3) .02
High-density lipoprotein 48 (9) 9 .001 40 (9) 0 .99 9 (5 to 13) .01
Triglycerides, mg/dL 150 (45) −19 .04 170 (47) −4 .67 −15 (−29 to −1) .05
Glucose, mg/dL 95 (8) −8 .02 103 (11) −1 .34 −7 (−12 to −2) .02
Insulin, µU/mL 14 (5) −7 .04 17 (7) −2 .09 −5 (−9 to −1) .04
Interleukin, pg/mL§
6 3.1 (0.9-7) −1.4 .04 4.5 (2.1-8.8) 0.1 .67 −1.5 (−2.9 to 0.3) .03
8 4.1 (1.3-8.9) −1.2 .05 4.7 (1.4-8.4) −0.3 .23 −0.9 (−2.0 to 0.3) .07
C-reactive protein, mg/L§ 1.9 (0.9-7.1) −1.4 .01 3.4 (1.3-8.2) 0 .67 −1.4 (−2.5 to −0.3) .02
Response to L-arginine
Platelet aggregation, % −11 (4.8) −7 .01 −4.3 (3.2) −0.7 .17 −6.3 (−9.3 to −3.3) .02
Mean blood pressure, mm Hg −5.1 (1.9) −2.6 .001 −2.6 (1.5) −0.2 .47 −2.4 (−3.2 to −1.6) .02
SI conversion factors: To convert total cholesterol and high-density lipoprotein cholesterol from mg/dL to mmol/L, multiply by 0.0259; triglycerides from mg/dL to mmol/L, multiply
by 0.0113; glucose from mg/dL to mmol/L, multiply by 0.0555; and insulin from µU/mL to pmol/L, multiply by 7.175.
*Data are presented as mean (SD) unless otherwise indicated.
†Calculated as weight in kilograms divided by the square of height in meters.
‡Based on the International Index of Erectile Function scale.
§Data are presented as median (interquartile range).
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lar pathways underlying both condi-
tions in obese men. A disturbance in
nitric oxide activity linked to reduced
nitric oxide availability could provide
a unifying explanation for this associa-
tion. In particular, in isolated corpus
cavernosum strips from patients with
erectile dysfunction both neurogenic
and endothelium-dependent relax-
ation is impaired.18 Moreover, erectile
dysfunction in diabetic men corre-
lates with endothelial dysfunction and
endothelial activation, including cir-
culating concentrations of P-selectin
and cellular adhesion molecules.19 In
addition to being a powerful indicator
of risk, recent evidence suggests that
CRP may directly participate in lesion
formation through leukocyte activa-
tion and endothelial dysfunction.20-22
This study provides evidence that
weight loss achieved by lifestyle
changes can ameliorate erectile func-
tion in obese men with erectile dys-
function at baseline. In the Massachu-
setts Male Aging Study, Derby et al16
found that men who were overweight
at baseline were at an increased risk
of developing erectile dysfunction
regardless of whether they lost weight
during follow-up. By contrast, men
who initiated physical activity in
midlife had a 70% reduced risk for
erectile dysfunction relative to those
who remained sedentary. In quantita-
tive terms, this means that sedentary
men may be able to reduce their risk
of erectile dysfunction by adopting
regular physical activity at a level of at
least 200 kcal/d, which corresponds to
walking briskly for 2 miles.23 In our
study, about one third of obese men
with erectile dysfunction regained
their sexual function after 2 years of
adopting healthy behaviors, mainly
regular exercise and reducing weight.
This may be in line with epidemiologi-
cal evidence that physical activity was
associated with a 30% lower risk of
erectile dysfunction, while obesity was
associated with a 30% higher risk of
erectile dysfunction.4 Additionally,
men in the intervention group showed
improvement in the number of surro-
gate traditional and novel cardio-
vascular risk factors, which were bet-
ter than those seen in men in the
control group.
Obesity is a state of chronic oxida-
tive stress and inflammation.24 The in-
creased oxidative stress associated with
obesity may increase free radical for-
mation, which could quench and de-
activate nitric oxide, reducing its avail-
ability for target cells. Obese men
participating in weight loss programs
with dietary modifications and in-
creased physical activity experienced re-
duced oxidative stress associated with
improved nitric oxide availability.25 As
impaired nitric oxide activity appears
to play an important role in the patho-
genesis of erectile dysfunction,26 im-
proved nitric oxide availability associ-
ated with weight loss may be implicated
in the amelioration of erectile func-
tion in our series of obese men. A re-
duced CRP level due to sustained life-
style changes may have contributed to
amelioration of erectile function after
treatment. Levels of CRP correlate sig-
nificantly with reduced nitric oxide
availability22 and increasing severity of
penile vascular disease as measured by
penile Doppler.27 Moreover, consis-
tent findings support a predictive role
of CRP and IL-6 for cardiovascular
events in different populations,28 while
IL-8 is a potent chemoattractant.29
Our study has several limitations. Psy-
chological factors or relational situa-
tions may negatively influence erectile
activity,30 so it is entirely possible that
improvement in mental health through
alleviation of anxiety and depression in
the intervention group, as well as im-
provement in self-image of the obese pa-
tient after weight loss, may have played
a role in the results. Because the aim of
the study was to assess the role of life-
style changes on endothelial and erec-
tile dysfunction, we did not assess psy-
chological profiles of the participants.
However, it seems unlikely that psycho-
logical factors also played an important
role in the amelioration of endothelial
function at the end of the study. Our
findings may not be totally generaliz-
able to primary care populations be-
cause the intervention was intensive and
involved a lot of contact with the study
team. However, this should not detract
from the potential importance of the
findings for public health in the light of
the increasing evidence that sustained
lifestyle modifications have a profound
impact on diseases.
Our data demonstrate that lifestyle
changes, including a reduced calorie
diet and increased exercise, improve
erectile function in obese men and re-
sulted in about one third of men with
erectile dysfunction regaining sexual
function after treatment. This improve-
ment was associated with ameliora-
tion of both endothelial function and
markers of systemic vascular inflam-
mation. Interventions focused on modi-
fiable health behaviors may represent
a safe strategy to improve erectile func-
tion and reduce cardiovascular risk in
obese patients.
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